Results 81 to 90 of about 66,662 (177)

Development, Early Verification and Application of a North American Pediatric PBPK Model, Comparison With the North European Pediatric Population

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
ABSTRACT Physiologically based pharmacokinetic (PBPK) models are increasingly used in pediatric drug development and matching such models to the target population is an important consideration. A US pediatric PBPK model was developed incorporating four sub‐groups describing physiology and enzymatic/transporter levels for White, African American ...
Trevor N. Johnson, Fiskani Kondowe, Joyce van der Heijden, Saskia N. de Wildt, Iain Gardner, Karen Rowland Yeo   +5 more
wiley   +1 more source

Early Acute Kidney Injury in Allogeneic Hematopoietic Cell Transplantation: Incidence, Severity, and Associated Factors in a 634‐Recipient Cohort

European Journal of Haematology, Volume 117, Issue 4, Page 981-994, October 2026.
ABSTRACT Background Acute kidney injury (AKI) is a frequent and clinically relevant complication in allogeneic hematopoietic cell transplantation (HCT) recipients, particularly during the early post‐HCT period. Although AKI has been extensively reported in long‐term follow‐up studies, data focusing on the initial hospitalization phase remain limited ...
Luiz Carlos da Costa‐Junior, Rita de Cássia Barbosa da Silva Tavares, Marina Izu, Simone Cunha Maradei, Maria Claudia Rodrigues Moreira, Marta Colares Nogueira, Décio Lerner, Fabrício Guimarães Bino, Patrícia Moriel, Teresa de Souza Fernandez, Paulo Caleb Júnior Lima Santos   +10 more
wiley   +1 more source

Lung Transplantation Outcomes and Peritransplant Sirolimus Use in Lymphangioleiomyomatosis

Annals of Thoracic Surgery Short Reports
Background: With the introduction of sirolimus as medical therapy for lymphangioleiomyomatosis (LAM), an updated evaluation of LAM lung transplant (LT) outcomes and characterization of peritransplant sirolimus use is needed.
Emily L. Larson, BS, Reed T. Jenkins, BA, Jessica M. Ruck, MD, Laura B. Zeiser, MS, Alice L. Zhou, MS, Alfred J. Casillan, MD, PhD, Dorry L. Segev, MD, Allan B. Massie, MD, Jinny S. Ha, MD, Pali D. Shah, MD, Christian A. Merlo, MD, MPH, Errol L. Bush, MD   +11 more
doaj   +1 more source

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1702-1712, October 2026.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn, Alexandre O. Gérard, Maëlys Labat, Zoe Apalla, Wouter van Binsbergen, Dimitra Koumaki, Valerian Rivet, Frederic Dezoteux, Damien Giacchero, Michael R. Ardern‐Jones, Kara Heelan, Jesse P. Hirner, Ander Mayor, Mariette Labots, Markus V. Starink, Conny J. van der Laken, Vincent Sibaud, Yannick S. Elshot   +17 more
wiley   +1 more source

Sirolimus

Reactions Weekly, 2006
europepmc   +2 more sources

A Case of Disseminated Encephalitozoon cuniculi in a Lung Transplant Recipient: Microsporidiosis in the Era of Molecular Diagnostics

Transplant Infectious Disease, EarlyView.
Lee S. Gottesdiener, Clare DeLaurentis, Marcus R. Pereira   +2 more
wiley   +1 more source

Prospective study of safety, immunogenicity, and efficacy of inactivated COVID-19 vaccine in tuberous sclerosis complex children on sirolimus

Human Vaccines & Immunotherapeutics
While sirolimus is widely used in tuberous sclerosis complex (TSC), its impact on coronavirus disease 2019 (COVID-19) vaccination remains unclear. To evaluate the safety, immunogenicity, and efficacy of inactivated COVID-19 vaccine on the children with ...
Sufang Lin, Xia Zhao, Lin Li, Qiru Su, Weiwei Long, Xiaoqin Tian, Jinghua Ye, Bixia Yuan, Yan Hu, Jianxiang Liao, Hongbing Zhang   +10 more
doaj   +1 more source

Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results

Annals of the Child Neurology Society
Objective Tuberous sclerosis complex (TSC) results from overactivity of the mechanistic target of rapamycin (mTOR). Sirolimus and everolimus are mTOR inhibitors that treat most facets of TSC but are understudied in infants.
Jamie K. Capal, David M. Ritter, David Neal Franz, Molly Griffith, Kristn Currans, Bridget Kent, E. Martina Bebin, Hope Northrup, Mary Kay Koenig, Tomoyuki Mizuno, Alexander A. Vinks, Stephanie L. Galandi, Wujuan Zhang, Kenneth D.R. Setchell, Kelly M. Kremer, Carlos M. Prada, Hansel M. Greiner, Katherine Holland‐Bouley, Paul S. Horn, Darcy A. Krueger   +19 more
doaj   +1 more source

Sirolimus for the treatment of vascular tumors and malformations in children: A 10-year single-institution retrospective study. [PDF]

World J Clin Pediatr
Thongngam N, Sathitsamitphong L, Morakote W, Chanthong S, Maneekesorn S, Natesirinilkul R, Charoenkwan P, Choed-Amphai C.   +7 more
europepmc   +1 more source

Two-Year Clinical Outcomes of Contemporary Drug-Eluting Stents Grouped by Eluted Limus Agent: A Retrospective Cohort Study. [PDF]

J Clin Med
Joo D, Byoun JT, Cho JY, Jo S, Yun KH.
europepmc   +1 more source